
HEK293/Cyno APJ Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0033L | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The APJ receptor (Apelin receptor, also known as APLNR) belongs to the Class A family of G protein-coupled receptors (GPCRs), which is the most extensively studied GPCR family and has the highest concentration of drug targets. The APJ receptor and its ligands are involved in numerous physiological functions and pathophysiological processes, making it a pivotal therapeutic target for future treatments of conditions such as ischemic heart disease, hypertension, and heart failure.
Screeningbio’s HEK293/Cyno APJ cell line overexpress APJ and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Macaca fascicularis (Cyno) |
HGNC Symbol | APLNR |
Accession Number | XM_005577873.4 |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
![HEK293/Cyno APJ Agonist Assay. HEK293/Cyno APJ cells were stimulated with 5 μM Forskolin and treated with reference agonist Apelin-13. The assay was run based on Revvity cAMP HTRF protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.](https://static.wixstatic.com/media/cbf7de_839d773e6de74f54adc2ab007a3c8c5e~mv2.png/v1/fill/w_75,h_75,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/cbf7de_839d773e6de74f54adc2ab007a3c8c5e~mv2.png)
Target Background
The APJ receptor (Apelin receptor, also known as APLNR) belongs to the Class A family of G protein-coupled receptors (GPCRs), which is the most extensively studied GPCR family and has the highest concentration of drug targets.
The APJ receptor and its ligands are involved in numerous physiological functions and pathophysiological processes, making it a pivotal therapeutic target for future treatments of conditions such as ischemic heart disease, hypertension, and heart failure.
